Literature DB >> 12749229

Budding as a useful determinant of the optimal treatment for T1 rectal carcinomas.

Tadahiko Masaki1, Hiroyoshi Matsuoka, Masanori Sugiyama, Nobutsugu Abe, Toshiyuki Mori, Yutaka Atomi, Toshiaki Watanabe, Hirokazu Nagawa, Tetsuichiro Muto.   

Abstract

BACKGROUND/AIMS: If a locally excised specimen has poorly differentiated or undifferentiated histology, positive vascular invasion, or massive invasion to the cut end or a positive margin, additional surgery is recommended for the treatment of T1 rectal carcinoma. However, positive predictive values of these histological criteria are low. This study was undertaken to clarify more reliable risk factor(s) for lymph node metastasis in T1 rectal carcinomas.
METHODOLOGY: In 58 patients with T1 rectal carcinoma undergoing local excision or radical surgery, the associations between lymph node metastasis or intrapelvic recurrence and clinicopathological features were studied using multiple regression analysis with special reference to tumor budding at the invasive front.
RESULTS: Lymph node metastasis was observed in 1 of 9 patients undergoing additional bowel resection after local excision, and in 2 of 24 patients undergoing radical surgery alone. Intrapelvic extrarectal recurrence was observed in 3 of 25 patients undergoing local excision alone. Logistic regression analysis revealed that budding at the invasive front alone was significantly associated with lymph node metastasis or intrapelvic recurrence (p = 0.0484).
CONCLUSIONS: Additional bowel resection with lymph node dissection should be recommended for locally excised T1 rectal carcinoma with budding at the invasive front.

Entities:  

Mesh:

Year:  2003        PMID: 12749229

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas.

Authors:  Nobuyuki Ohike; Ipek Coban; Grace E Kim; Olca Basturk; Takuma Tajiri; Alyssa Krasinskas; Sudeshna Bandyopadhyay; Toshio Morohoshi; Yuki Shimada; David A Kooby; Charles A Staley; Michael Goodman; N Volkan Adsay; Nazmi Volkan Adsay
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

2.  Pathological predictors for lymph node metastasis in T1 colorectal cancer.

Authors:  Hitoshi Yamauchi; Kazutomo Togashi; Yutaka J Kawamura; Hisanaga Horie; Junichi Sasaki; Shingo Tsujinaka; Yoshikazu Yasuda; Fumio Konishi
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

3.  Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type.

Authors:  Dae Kyung Sohn; Hee Jin Chang; Ji Won Park; Dong Hyun Choi; Kyung Su Han; Chang Won Hong; Kyung Hae Jung; Dae Yong Kim; Seok-Byung Lim; Hyo Seong Choi; Seung-Yong Jeong
Journal:  J Clin Pathol       Date:  2006-09-22       Impact factor: 3.411

Review 4.  Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases.

Authors:  Sean C Glasgow; Joshua I S Bleier; Lawrence J Burgart; Charles O Finne; Ann C Lowry
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

5.  Tumor budding and recurrence in submucosal invasive colorectal cancers of favorable histology: case reports of two early colorectal cancers with advanced recurrences.

Authors:  Heae Surng Park; Hee Jin Chang; Ji Won Park; Byung Chang Kim; Dae Kyung Sohn; Chang Won Hong; Ji-Yeon Baek; Sun Young Kim; Hyo Seong Choi; Jae Hwan Oh
Journal:  Korean J Pathol       Date:  2012-06-22

6.  Histopathological features predict metastatic potential in locally advanced colon carcinomas.

Authors:  Caren Jayasinghe; Nektaria Simiantonaki; Charles James Kirkpatrick
Journal:  BMC Cancer       Date:  2015-01-21       Impact factor: 4.430

Review 7.  When is local excision appropriate for "early" rectal cancer?

Authors:  Kotaro Maeda; Yoshikazu Koide; Hidetoshi Katsuno
Journal:  Surg Today       Date:  2013-11-21       Impact factor: 2.549

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.